

Special Issue

Radiomics: Unlocking Personalized Insights from Medical Images

Message from the Guest Editors

Radiomics converts medical images into quantitative biomarkers to assess cancer risk, understand biology, and guide treatment. Early work showed prognostic value of intratumoral features; recent studies highlight peritumoral habitats and multimodal data integration. We invite validated, clinically interpretable, and generalizable methods and applications across the cancer spectrum—from risk assessment and prevention to diagnosis, therapy, and outcome monitoring. Key areas include feature robustness, harmonization, delta-radiomics, external validation, clinical utility, and multimodal integration for patient stratification. Studies demonstrating how peritumoral signatures improve staging, risk, and response, as well as large-cohort research, reproducibility, bias mitigation, and model governance, are especially welcome. **We solicit submissions on:** intratumoral + peritumoral modeling; feature robustness and harmonization; delta-radiomics; external validation; multimodal fusion; large-cohort studies; reproducibility, bias, governance; and reviews/tutorials with open code/data.

Guest Editors

Dr. Genti Xhepa

Dr. Baptiste Bonnet

Dr. Alexis Ricoeur

Deadline for manuscript submissions

25 July 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/253278

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).